Natrol, Chatsworth, CA, and Next Pharmaceutical, Irvine, CA, have developed a line of products featuring Nexrutine™, a dietary ingredient that acts as a natural inhibitor of the COX-2 enzyme. The product, which will be available this fall, will be marketed under the Flexanew name. Nexrutine™ has been shown to selectively inhibit COX-2 without any inhibition of COX-1, a stomach-protecting enzyme. Nexrutine™ will be exclusively manufactured by RJ Reynolds’ Avoca Division.